Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xoma Royalty Corporation
(NQ:
XOMA
)
29.00
-0.47 (-1.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xoma Royalty Corporation
< Previous
1
2
3
Next >
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
August 13, 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024
From
XOMA Corporation
Via
GlobeNewswire
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
July 09, 2024
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.
Via
Benzinga
Exposures
Product Safety
Demystifying XOMA: Insights From 5 Analyst Reviews
July 09, 2024
Via
Benzinga
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2024
From
XOMA Corporation
Via
GlobeNewswire
Peeling Back The Layers: Exploring XOMA Through Analyst Insights
May 31, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For XOMA
April 29, 2024
Via
Benzinga
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
June 12, 2024
From
XOMA Corporation
Via
GlobeNewswire
3 Crazy Good Stocks to Buy With $500 Right Now
June 12, 2024
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.
Via
InvestorPlace
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Recap: XOMA Q4 Earnings
March 08, 2024
Via
Benzinga
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right
From
XOMA Corporation
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
March 25, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
From
XOMA Corporation
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
March 19, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
March 13, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
March 08, 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024
From
XOMA Corporation
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
February 20, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
February 16, 2024
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.
Via
Benzinga
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
From
XOMA Corporation
Via
GlobeNewswire
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
From
XOMA Corporation
Via
GlobeNewswire
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.